Legal & General Group Plc decreased its position in AtriCure, Inc. (NASDAQ:ATRC) by 1.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,216 shares of the medical device company’s stock after selling 112 shares during the period. Legal & General Group Plc’s holdings in AtriCure were worth $157,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ATRC. Neuberger Berman Group LLC bought a new position in shares of AtriCure during the first quarter worth about $10,849,000. Wellington Management Group LLP increased its position in shares of AtriCure by 5.6% in the first quarter. Wellington Management Group LLP now owns 3,313,575 shares of the medical device company’s stock worth $63,456,000 after buying an additional 176,025 shares during the period. FMR LLC increased its position in shares of AtriCure by 2.7% in the first quarter. FMR LLC now owns 4,950,000 shares of the medical device company’s stock worth $94,793,000 after buying an additional 130,000 shares during the period. Wells Fargo & Company MN increased its position in shares of AtriCure by 131.9% in the first quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock worth $2,145,000 after buying an additional 63,711 shares during the period. Finally, Lockheed Martin Investment Management Co. bought a new position in shares of AtriCure during the first quarter worth about $1,216,000. Institutional investors own 86.06% of the company’s stock.

AtriCure, Inc. (NASDAQ:ATRC) traded up 0.34% during midday trading on Tuesday, reaching $23.42. The company had a trading volume of 32,907 shares. The company has a 50-day moving average price of $23.70 and a 200-day moving average price of $20.66. The stock’s market capitalization is $804.10 million. AtriCure, Inc. has a one year low of $14.35 and a one year high of $25.18.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $45.23 million during the quarter, compared to analyst estimates of $44.15 million. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. AtriCure’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.26) EPS. On average, equities analysts expect that AtriCure, Inc. will post ($0.95) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Legal & General Group Plc Has $157,000 Stake in AtriCure, Inc. (ATRC)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/15/legal-general-group-plc-has-157000-stake-in-atricure-inc-atrc.html.

A number of equities analysts have recently issued reports on ATRC shares. Zacks Investment Research upgraded AtriCure from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Tuesday, May 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 target price on shares of AtriCure in a research note on Monday, April 17th. ValuEngine raised AtriCure from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $26.00 target price on shares of AtriCure in a research note on Tuesday, May 30th. Finally, TheStreet raised AtriCure from a “d+” rating to a “c-” rating in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $25.00.

In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total transaction of $214,400.00. Following the completion of the transaction, the director now owns 24,162 shares of the company’s stock, valued at approximately $518,033.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.00% of the company’s stock.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.